March 10, 2011
Benlysta Approved for Systemic Lupus Erythematosus
Belimumab is a human monoclonal antibody drug that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, or BLyS. BLyS is a naturally occurring protein required for the survival and maturation of B-lymphocyte cells into plasma B cells. In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body's own healthy tissues.
Benlysta is expected to be available within the next two weeks.
For more information call (301) 309-8504 or (888) 825-5249 or visit www.hgsi.com or www.gsk.com.